FDA Approves LACOSAMIDE — MSN LABORATORIES PRIVATE LIMITED
MSN LABORATORIES PRIVATE LIMITED has received approval for its ANDA 204921 for lacosamide, enabling the launch of the generic version of the oral drug. This approval expands distribution options for the seizure treatment and is expected to intensify generic competition in the neuropsychiatric market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed